medical decision support medical decision support
Sign In

Predictive Factors of Ando et al for Antitumor Response and Survival in a Patient with Non-Small Cell Lung Cancer Treated with Gefitinib

Description

Ando et al listed predictors for response and survival for a patient with non-small cell lung cancer (NSCLC) treated with gefitinib. These can help to identify which patients should receive this therapy. The authors are from Kyoto University, Kinki University, Shizuoka Cancer Center, Osaki City General Hospital, Tokai University and the Aichi Cancer Center in Japan.


 

Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.

 

Patient selection: Japanese adult with non-small cell lung carcinoma (NSCLC)

 

Predictors of a response to gefitinib and survival:

(1) female gender

(2) history of never smoking (defined as < 100 cigarettes ever smoked)

(3) adenocarcinoma

(4) good ECOG performance status (ECOG 0 or 1)

 

Additional predictors for response:

(1) metastatic disease

 

Additional predictors for survival:

(1) nonmetastatic disease

(2) previous chest surgery (probably indicative of resectable lung tumor)

 


To read more or access our algorithms and calculators, please log in or register.

Specialty

ICD-10